Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 33Terminated 13Active not recruiting 9Recruiting 7Withdrawn 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 20Lymphoid 7Other solid neoplasm 2Gastrointestinal 2Classical hematology 2Plasma cell 1Myeloid 1Gynecologic 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Imatinib Mesylate 17Cytarabine 13Azacitidine 13Cyclophosphamide 11Decitabine 9Dasatinib 9Etoposide 8nilotinib 7Peripheral Blood Stem Cell Transplantation 7Busulfan 7Tacrolimus 6Polymerase Chain Reaction 6Idarubicin 6Blood Specimen Collection 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5ruxolitinib 4pegaspargase 4fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Methylprednisolone 4Hydroxyurea 4Filgrastim 4ponatinib 3Surveys and Questionnaires 3Rituximab 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Granulocyte Colony-Stimulating Factor × Myeloid × Clear all
NCT03356080 2017-11-29

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Shanghai Tong Ren Hospital

Phase 2 Unknown
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡